Perrigo | PRGO - Cash And Equivalent


Perrigo reported $432.1M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
AbbVie USD 5.23B 400M Dec/2025
Abbott USD 8.52B 1.01B Dec/2025
Bayer EUR 5.9B 1.34B Sep/2025
Bristol-Myers Squibb USD 10.21B 5.52B Dec/2025
Coherus Biosciences USD 103.35M 113.54M Sep/2025
Corcept Therapeutics USD 120.49M 4.64M Dec/2025
Dr.Reddys Laboratories INR 18.66B 8.75B Dec/2025
Eli Lilly USD 7.27B 2.52B Dec/2025
J&J USD 19.71B 1.48B Dec/2025
Merck USD 18.17B 10.16B Sep/2025
Nestle CHF 4.65B 904M Jun/2025
Pacira USD 147.59M 152.89M Sep/2025
Perrigo USD 432.1M 22.1M Sep/2025
Pfizer USD 1.34B 295M Sep/2025
Phibro Animal Health USD 55.49M 17.28M Dec/2025
Prestige Brands USD 62.37M 56.73M Dec/2025
Reckitt Benckiser GBP 880M 106M Dec/2024
Sanofi EUR 7.66B 1.25B Dec/2025
Supernus Pharmaceuticals USD 151.37M 6.66M Sep/2025
Teva Pharmaceutical Industries USD 3.56B 1.35B Dec/2025
Xeris Pharmaceuticals USD 91.6M 32.32M Sep/2025
Zoetis USD 2.08B 649M Sep/2025